ERD

Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refr...

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

MEANS AND METHODS FOR TREATING CANCER

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after all...

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without...

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Epigenetics in myelodysplastic syndromes

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic ...

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATING AGENTS (HMA)

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Periodic Reporting for period 4 - PNANOMED (Personalized Nanomedicines for Leukemia Patients)

Project: PNANOMED

Updated at: 27-04-2024

Show more information

Project acronym PNANOMED

Resources